Abstract
Neurotrauma Rep. 2026 Oct 7;7:2689288X261477535. doi: 10.1177/2689288X261477535. eCollection 2026 Jan-Dec.
ABSTRACT
Given the prevalence of mild traumatic brain injury (mTBI) and sports-related concussion, the development of efficient diagnosis methods is essential. Although magnetic resonance imaging (MRI) and computed tomography are standard imaging modalities in traumatic brain injury assessment, they frequently fail to detect the subtle structural and metabolic changes associated with mTBI. Furthermore, while cognitive tests like the Immediate Post-Concussion Assessment and Cognitive Testing and the Sports Concussion Assessment Tool 5 have been developed, fluid-based biomarkers provide a cheaper and quicker method to identify mTBI. Using the PubMed database, we searched for English-language articles on mTBI biomarkers. Conventional biomarkers (e.g., glial fibrillary acidic protein, neuron-specific enolase, tau) frequently show statistically significant group-level differences after mTBI, but their individual-level diagnostic performance is often moderate, with overlapping distributions. As a result, single markers alone may not reliably distinguish mTBI from controls or from other neurological conditions. Biomarkers can detect differences between mTBI and control patients, but the literature suggests that detectors such as neurogranin are not significant indicators of mTBI. Moreover, studies showed that alpha-synuclein increases during the acute phase of mTBI, yet it has been found that lower α-synuclein levels are associated with mTBI in trauma patients. Due to these discrepancies, multi-biomarker panels may be the most comprehensive way to detect mTBI in the acute phase. While some developments are promising, the limitations associated with the current biomarkers warrant comprehensive studies to assess their effectiveness. In clinical practice, these proteins are measured using automated electrochemiluminescence immunoassays that are inexpensive, allow single-sample testing, and yield results in ∼20 min. Access is the constraint, as these analyzers are hospital-based; therefore, point-of-care (e.g., finger-prick) tests remain a priority. Conventional enzyme-linked immunosorbent assay are research tools and are less suitable for acute-care workflows. Attention should be directed toward the development of technologies to measure mTBI biomarkers pitch-side so that head injuries can be diagnosed immediately after injury.
PMID:43036479 | PMC:PMC13770030 | DOI:10.1177/2689288X261477535
UK DRI Authors